Cidara Therapeutics, Inc. stock is down -7.89% since 30 days ago. The next earnings date is Mar 21, 2024. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 55.56% of the previous 8 November’s closed higher than October. 100% of analysts rate it a buy.
Cidara Therapeutics, Inc. focuses on the discovery, development, and commercialization of long-acting anti-infectives. The company's lead product candidate is rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of invasive fungal infections, including candidemia and invasive candidiasis.